Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
31 août 2023 07h00 HE
|
Jnana Therapeutics, Inc.
JNT-517 demonstrated sustained, dose-dependent pharmacodynamic effects and was safe and well tolerated in healthy volunteers Phase 1b study is ongoing in individuals with PKU BOSTON, Aug. 31, 2023 ...
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 in Individuals with PKU
09 août 2023 07h00 HE
|
Jnana Therapeutics, Inc.
JNT-517 is a Potential First-in-Class Oral Treatment for PKU; Phase 1b Study Follows Positive Clinical Proof of Mechanism Data in Healthy Individuals Upcoming Oral Presentation of Phase 1a Study...
Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D
19 juil. 2023 07h00 HE
|
Jnana Therapeutics, Inc.
BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for...
Jnana Therapeutics to Present at the Jefferies Healthcare Conference
01 juin 2023 07h00 HE
|
Jnana Therapeutics, Inc.
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets,...
Jnana Therapeutics Reports Positive Topline Results from Phase 1a Clinical Study of JNT-517, a Potential First-in-Class Oral Treatment for PKU
31 mai 2023 07h00 HE
|
Jnana Therapeutics, Inc.
JNT-517 demonstrated proof of mechanism and was safe and well tolerated in healthy volunteers Results support advancement to Phase 1b study in individuals with PKU; study now open for enrollment ...
Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche
24 mai 2023 07h00 HE
|
Jnana Therapeutics, Inc.
Achievement of research milestone for immune program triggers milestone payment BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its...